RECURSION PHARMACEUTICALS INC CLAS (RXRX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for RXRX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| RXRX | Chief Executive Officer and President | 42 | ["Chief Research and Development Officer","Chief Commercial Officer","Chief Data Science Officer","Senior Vice President/Global Head, Strategy and Portfolio Organization, R&D","Senior Vice President/Global Head, Strategy and Operations, R&D","Chief Operating Officer, R&D Data Science","Head of R&D Strategic Initiatives","Co-chair of Data Science Council at Johnson and Johnson","Partner within the Healthcare Practice at The Boston Consulting Group","Ph.D. in Organic Chemistry","B.S. in Computational Chemistry"] | ["Strategic Transactions and Finance"] | 2026 |
Biography sourced from the proxy statement filing.
Najat Khan, Ph.D., has served as our Chief Executive Officer and President since January 2026 and as a member of our Board since April 2024. She previously held the roles of Chief Research and Development Officer and Chief Commercial Officer from July 2024 to December 2025. Prior to joining Recursion, Dr. Khan was the Chief Data Science Officer and Senior Vice President/Global Head, Strategy and Portfolio Organization, R&D, of Johnson and Johnson, which she held from June 2023 to June 2024 and she previously held the following roles with Johnson and Johnson: Chief Data Science Officer and Senior Vice President/Global Head, Strategy and Operations, R&D, from May 2020 to June 2023; Chief Operating Officer, R&D Data Science and Global Head, Strategy and Operations, R&D, from November 2019 to May 2020 and April 2019 to May 2020, respectively; and Head of R&D Strategic Initiatives from March 2018 to March 2019. She was also Co-chair of Johnson and Johnson s Data Science Council from February 2020 to June 2024. Dr. Khan progressed through several roles of increasing seniority at The Boston Consulting Group, culminating in her positions as Partner within the Healthcare Practice, from August 2011 to February 2018. Dr. Khan holds a Ph.D. in Organic Chemistry with a focus in Computational Chemistry from the University of Pennsylvania and a B.S. in Computational Chemistry from Colgate University with a minor in Economics/Business. Our Board believes Dr. Khan is qualified to serve on our Board because of her extensive experience in drug discovery, development, commercialization, Data Science and AI, as well as life sciences business leadership.